A new version is published in 2014
Prenant pour socle la vision Bénin 2025 Alafia, le Plan National de Développement 2018-2025 intègre les nouveaux enjeux de développe-ment économique et social au plan national, africain et international. Son élaboration a été un défi majeur que nous avons relevé, avec la contri-bution de t...ous les acteurs à divers niveaux : secteur public, secteur privé, institutions de la République, organisations de la société civile, parte-naires sociaux, Association Nationale des Communes du Bénin (ANCB), universitaires, Gouvernement et partenaires techniques et financiers. En unissant les efforts, le peuple béninois vient de se doter d’un outil ma-jeur de développement dont la mise en œuvre réussie offrira au Bénin l’opportunité triplement gagnante d’atteindre la Vision Bénin 2025 et de se mettre sur le sentier des Objectifs de Développement Durable (ODD) à l’horizon 2030 et de la Vision Africa 2063.
more
Int J Tuberc Lung Dis. 2019 Jul 1;23(7):858–864.Namibia ranks among the 30 high TB burden countries worldwide. Here, we report results of the second nationwide anti-TB drug resistance survey. To assess the prevalence and trends of multidrug-resistant TB (MDR-TB) in Namibia.
From 2014 to 2015, pat...ients with presumptive TB in all regions of Namibia had sputum subjected to mycobacterial culture and phenotypic drug susceptibility testing (DST) for rifampicin, isoniazid, ethambutol and streptomycin if positive on smear microscopy and/or Xpert MTB/RIF.
more
Malaria in pregnancy is a significant health problem in malaria-endemic areas. It not only causes substantial childhood morbidity and mortality but also increases the risks of adverse events for pregnant women and their developing fetuses. Most of the burden in these areas is due to infection with P...lasmodium falciparum. Artemisinin-based combination therapy (ACT) has been recommended as first-line treatment for uncomplicated P. falciparum malaria in all populations, including pregnant women in their second and third trimesters, since 2006. However, for women in their first trimester of pregnancy, WHO recommended as first-line treatment a combination of quinine and clindamycin.
Based on a review of the evidence conducted in 2022, WHO now recommends artemether–lumefantrine, the ACT with the most human safety data available, as the preferred treatment for uncomplicated P. falciparum malaria in the first trimester of pregnancy. This document presents all relevant evidence on the effects and safety in early pregnancy of artemisinins and partner medicines used in ACTs from both studies in experimental animals and observational studies in humans.
more
Malaria in children presents significant clinical challenges, with variations in presentation based on the malaria parasite involved and the child's underlying health conditions. The World Health Organization reports high incidence rates, particularly in sub-Saharan Africa, and emphasizes the import...ance of effective treatment strategies. First-line treatment often involves Artemether-Lumefantrine (ALu), while severe malaria requires careful management and the use of intravenous Quinine. Management protocols emphasize early diagnosis and the monitoring of severe complications to reduce mortality.
more
Le Plan Stratégique National de Lutte contre le Paludisme 2021–2027 du Burundi expose la vision d’un Burundi sans décès lié au paludisme d’ici 2027. Le programme vise à réduire de 60 % la morbidité et à atteindre zéro mortalité grâce à une couverture universelle en prévention (m...oustiquaires imprégnées, pulvérisation intradomiciliaire, traitement préventif intermittent), une prise en charge efficace à tous les niveaux (structures sanitaires et communautaires), un renforcement des capacités institutionnelles, et une surveillance épidémiologique renforcée. Le plan insiste sur la bonne gouvernance, l’équité, la mobilisation des ressources, la communication et l’innovation, tout en s’alignant sur les objectifs nationaux et internationaux de santé publique.
more
Despite being a preventable and curable infectious disease, tuberculosis (TB) has continued to elude global controll efforts. In 2023, 8.2 milion people with TB were diagnosed and notified to the WHO, the hightest number ever reported since WHO began tracking.
The Practical manual on laboratory strengthening, 2022 update provides practical guidance on implementation of WHO recommendations and best practices for TB laboratory strengthening. It is an updated version of the GLI Practical Guide to Laboratory Strengthening published in 2017 and provides the la...test practical guidance on use of newly recommended diagnostics as well as guidance in key technical areas, including quality assurance and quality management systems, specimen collection and registration, procurement and supply-chain management, diagnostic connectivity, biosafety, data management, human resources, strategic planning, and model algorithms. The key changes are:
inclusion of recent or updated WHO recommendations for tests to diagnose TB and detect drug resistance;
alignment with the latest WHO critical concentrations for phenotypic drug-susceptibility testing (DST) and the new definitions of pre-XDR-TB and XDR-TB;
updated information on building quality-assured TB testing and management capacity using the Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA) approach (Score-TB package1);
updated information on assessing, analysing and optimising TB diagnostic networks; and
updated information on the use of next-generation sequencing (NGS) to detect mutations associated with drug resistance for surveillance purposes.
The document also provides references to resources and tools relevant for work on laboratory strengthening.
more
This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document:
Broad spectrum Pan-African polyvalent antivenoms: products ...that are intended for widespread utility throughout sub-Saharan Africa for treatment of envenoming irrespective of the species of snake causing a bite. Monovalent antivenoms for specific use cases: for products for a single species (or genus) of snake (e.g., boomslangs or carpet viper antivenoms).
Syndromic Pan-African polyvalent antivenoms for neurotoxic envenoming: products that are intended for treatment of envenoming by species whose venoms are neurotoxic. Syndromic Pan-African polyvalent antivenoms for non-neurotoxic envenoming: products for snakebite envenoming where the effects are largely haemorrhagic, necrotic or procoagulant.
more
Schistosomiasis is a parasitic disease caused by infection with
Schistosoma trematodes. The disease affects poor rural communities
but has spread to urban areas and to tourists visiting endemic areas
Since 2000, concerted efforts by national programmes, supported by public–private partnerships, nongovernmental organizations, donors and academia under the auspices and coordination of the World Health Organization (WHO), have produced important achievements in the control of human African trypan...osomiasis (HAT). As a consequence, the disease was targeted for elimination as a public health problem by 2020. The Sixty-sixth World Health Assembly endorsed this goal in resolution WHA66.12 on neglected tropical diseases, adopted in 2013.
National sleeping sickness control programmes (NSSCPs) are core to progressing control of the disease and in adapting to the different epidemiological situations. The involvement of different partners, as well as the support and trust of long-term donors, has been crucial for the achievements.
more
This Community Conversation Kit (CCK) is designed to help people who have a leadership role speak with people in their community about how to protect themselves and those they care about from becoming ill with an infectious disease. This kit will help lead conversations that get people talking with ...each other and thinking differently about their health so they can take action. Using some simple tips and suggestions, the information in this kit will allow communities to exchange practical information that will help them know how to confidently protect their health.
more
The global emergence of antimicrobial resistance (AMR) is posing a threat to human health. Putting resources into the containment of AMR – including surveillance – is one of the highest-yield investments a country can make to mitigate its impact. In 2015, WHO launched the Global Antimicrobial Re...sistance Surveillance System (GLASS), the first global collaborative effort to foster AMR surveillance in bacteria causing acute infections. As of December 2018, 71 countries are enrolled in GLASS. The aim of this report is to document participation efforts and outcomes across these countries, and highlight differences and constraints identified to date. This report follows on from the first GLASS Report – Early implementation 2016-17, published in January 2018, and drawing on data from GLASS first data call in 2017.
more
This edition of UNICEF’s annual Humanitarian Action for Children highlights UNICEF’s funding appeal, which sets out an ambitious agenda to address the major challenges facing children and young people living through conflict and crisis. It presents the investments needed in 2021 to save their li...ves and protect their futures.
more
How WHO works to prevent drug use, reduce harm and improve safe access to medicines